GlassScriptPhysician profile
Lisa Michelle Grummer
NPI 1124096151
$2,969.83
in general payments reported to CMS, 2019-2025
26 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Obstetrics & Gynecology (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $861 · 2022: $756 · 2023: $558 · 2024: $658 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,340 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,339.52 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $407.44 | 2021-2024 | |
| Aspira Women'S Health INC | $405.65 | 2021-2022 | |
| Astellas Pharma US INC | $313.98 | 2022-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $235.81 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $233.32 | 2021-2024 | |
| Exeltis, USA INC. | $203.42 | 2021-2023 | Slynd |
| Organon LLC | $131.91 | 2021-2025 | Nexplanon |
| Myriad Women'S Health, INC. | $98.08 | 2023 | Myrisk |
| Pfizer INC. | $94.19 | 2022-2024 | |
| Novo Nordisk INC | $88.98 | 2024 | Wegovy |
| Therapeuticsmd, INC. | $87.58 | 2021-2022 | |
| Shield Therapeutics INC | $80.65 | 2023-2025 | Accrufer |
| Merck Sharp & Dohme LLC | $76.31 | 2021-2023 | Gardasil 9 |
| Sumitomo Pharma America, INC. | $73.48 | 2023-2024 | Myfembree |
| Abbott Laboratories | $68.28 | 2023-2024 | Freestyle Libre 3 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $66.62 | 2022 | |
| Avion Pharmaceuticals | $65.81 | 2021-2022 | |
| Millicent US INC | $53.66 | 2024-2025 | Intrarosa, Femring |
| Mylan Pharmaceuticals INC. | $44.85 | 2022 | |
| Ethicon US, LLC | $38.28 | 2021 | |
| Evofem Biosciences, INC. | $29.25 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $17.36 | 2023 | Exparel |
| Urovant Sciences INC | $17.12 | 2022 | |
| Becton, Dickinson and Company | $14.37 | 2023 | Bd Max System, Bd Max Instrument |
| Agile Therapeutics, INC. | $12.22 | 2022 | |
| Myovant Sciences INC. | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Grummer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.